Argent Biopharma Ltd · ASX:RGT
Argent Biopharma — MGC Pharmaceuticals — 3rd Annual CG Cannabis Conference May 2019
21 slides from Argent Biopharma's conference presentation, May 2019
Slide 1: Leading The Way in Cannabis Derived Medicines
OVERVIEW MARKET APPENDIX Leading The Way in Cannabis Derived Medicines with a Seed-to Pharmacy Strategy Company Presentation 3rd Annual CG Cannabis Conference May 2019
Slide 2: Disclaimer
Disclaimer OVERVIEW This presentation has been prepared by MGC Pharmaceuticals Limited (“Company”). It does not purport to contain all Those intentions, expectations, future plans, strategy and prospects may or may not be achieved. They are based on the information that a prospective investor may re
Slide 3: Summary
Summary OVERVIEW • A European Bio-Pharma Company with a “Seed to Pharmacy” strategy • Cost-effective, high-quality, standardised Cannabinoids derived medicines • Three pharmaceutical products in late stage development • ASX listed since 2016 with a market cap of A$70+ million Czech Republic: Botanic
Slide 4: In Numbers
In Numbers OVERVIEW Established leader in the cannabis space 3 Over 30 3 MARKET Operations Years Experience Developed Facilities R&D team backed by products Malta, Slovenia & extensive industry And pipeline of potential Czech Republic experience products in development APPENDIX Cannabis for Network
Slide 5: Global Market
Global Market OVERVIEW Estimated Cannabis for Cannabis based medicine Europe expected to be Nov 1st 2018 Medicinal use value sales to increase by largest medical cannabis UK legalised prescription MARKET US$58 billion 182% market. Total healthcare of medical cannabis in 2028 2016-2020 spend: €2.3t p
Slide 6: Global Market Potential
Global Market Potential OVERVIEW • MGC Pharma aims to secure a significant share in the global Cannabis Pharmaceutical Market • MGC Pharma targets large markets, where cannabis for medical uses is likely to have a high degree of success • 3 pharmaceutical products in late stage development MARKET Po
Slide 7: Board of Directors
Board of Directors OVERVIEW Highly qualified team with over 15 years of relevant experience MARKET Roby Zomer Brett Mitchell Nativ Segev Dr. Stephen Parker Dr. Ross Walker Managing Director & Co. Founder Executive Chairman Director of Business Strategy & Director Director & Founder Head of Medical A
Slide 8: Scientific Team
Scientific Team OVERVIEW Leading experts in the medical cannabis space with unparalleled expertise MARKET Dr. Johnny Grunfeld Professor Uri Kramer Professor David Professor Stane Srčič Chief Scientific Officer Head of Neurology product development Neubauer Certified in Israel, with clinical One of t
Slide 9: Vision
Vision OVERVIEW Building an industry leading global bio-pharma company 1. Engage in continuous research to maintain cutting edge position– Botanical and Pharmaceutical MARKET 2. Advance commercialisation strategy into targeted global geographies 3. Strengthen partnerships to promote new pipeline of
Slide 10: Company Snapshot
Company Snapshot OVERVIEW MGC Pharma is at the forefront of Global Phyto-Cannabinoid based medicines FIRST PRODUCT TO MARKET BEST-IN-CLASS MANUFACTURING • CannEpil™ is a phyto-cannabinoid product • EU GMP certification granted for production of aimed for drug-resistant epilepsy Phyto-Cannabinoid bas
Slide 11: Seed to Pharmacy Manufacturing
Seed to Pharmacy Manufacturing OVERVIEW Creation and Commercialisation of Phytocannabinoid-based products Global Operation New Centralised EU Hub • Multi-National • Maltese Facility to become primary • Pharma European R&D HQ in Slovenia operations hub • Cultivation R&D in both Slovenia and • Fully i
Slide 12: Products – Pharmaceuticals
Products – Pharmaceuticals OVERVIEW Targeting specific medical conditions such as epilepsy and Alzheimer's Phase I • Oral oil solution to • GMP certified oral • BiActive Capsule for Phase II treat seizures spray utilising a symptoms of Crohn’s associated with drug specific THC:CBD disease and Irrita
Slide 13: CannEpil™
CannEpil™ OVERVIEW CannEpil™ is a Cannabinoid-based IMP used as a treatment for refractory epilepsy • Authorized to prescribe in Australia and CannEpil™ is an oral oil solution of UK through Early Patient Access Scheme cannabidiol (CBD) and (-)- trans-Δ9- Neurological Disorders • Over 500,000 Epilep
Slide 14: CogniCann™
CogniCann™ OVERVIEW CogniCann™ designed to improve Dementia and Alzheimer patients quality of life • Authorized to prescribe in Australia and CogniCann™ is sublingual spray of UK through Early Patient Access Scheme cannabidiol (CBD) and (-)- trans-Δ9- Neurological Disorders • Over 800,000 Dementia p
Slide 15: Product Differentiators
Product Differentiators OVERVIEW Establishing a definitively exemplary market reputation Controls ensure that each product Developed by highly experienced contains same amount of team with specialist expertise Active Pharmaceutical ingredient MARKET QUALITY COMPLIANCE CONSISTENCY COST APPENDIX Produ
Slide 16: Research and Development
Research and Development OVERVIEW • Developing pharmaceutical grade products that leverage its proprietary medical cannabis formula through successful clinical trials in Europe, Australia and Israel • This will enable future medical product sales across the EU, Australia and other geographies, follo
Slide 17: Commercial Production: Malta
Commercial Production: Malta OVERVIEW MGC Pharma signs contract for full medical Medical Cannabis legalised in Malta – provides cannabis facility direct access to the EU The licence is subject to final legislative changes and Malta is highly strategic for the success of the Company’s presidential si
Slide 18: Malta: Providing Direct Access to the EU
Malta: Providing Direct Access to the EU OVERVIEW Establishing a fully vertically integrated medical cannabis “Seed to Pharmacy” operation in the EU EU/UK +5000m2 Maltese Medical Cannabis Production Facility US$58bn market by 2028 Research Greenhouse Facility GMP Production and Manufacturing Facilit
Slide 19: Distribution Partners
Distribution Partners OVERVIEW Extensive network in place providing access to hospitals, pharmacies and research institutions around the world Distribution agreement Distribution agreement Supply & Distribution Supply & Distribution Exclusive distribution MARKET with Health House and with Grow Biote
Slide 20: Investment Case
Investment Case OVERVIEW Fully Integrated Model: Grow Develop Commercialise Built on Decades of Experience Technical team of globally recognised scientists and doctors Focussed Operations MARKET Two core divisions: Research and Development Seed-to-Pharmacy – medicinal and nutraceuticals Strategi
Slide 21: OVERVIEW APPENDIX
OVERVIEW https://mgcpharma.com.au/ MARKET @mgcpharamaceuticals @MGC_Pharma MGC Pharmaceuticals Ltd. APPENDIX Financial PR: St Brides Partners (+44) 02072361177 info@stbridespartners.co.uk
MGC Pharmaceuticals — 3rd Annual CG Cannabis Conference May 2019 on 6ix